shire map
Select a
Location

Shire Global

Newsroom

Directorate change

February 15, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces the following changes to Board committee membership, effective immediately:

Director

Appointment

Resignation

Dominic Blakemore

Remuneration Committee

N/A

Olivier Bohuon

Nomination & Governance Committee

Science & Technology Committee

Ian Clark

Remuneration Committee;
Science & Technology Committee

N/A

Sara Mathew

Nomination & Governance Committee

Remuneration Committee

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations  
Ian Karpikarp@shire.com+1 781 482 9018
Robert Coatesrcoates@shire.com+44 1256 894874
Media  
Lisa Adlerlisa.adler@shire.com+1 617 588 8607
Debbi Forddebbi.ford@shire.com+1 617 949 9083

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com

Cookie Use Notification

The site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies as set out in our cookie notice. Please read our privacy notice for more information on the cookies we use and how to delete or block the use of cookies. LEARN MORE